Idenix Pharmaceuticals Inc (IDIX)

24.50
0.05 0.20
Prev Close 24.45
Open 24.49
Day Low/High 24.46 / 24.50
52 Wk Low/High 2.93 / 24.50
Volume 5.09M
Avg Volume 2.96M
Exchange
Shares Outstanding 151.50M
Market Cap 3.71B
EPS -0.91
Div & Yield N.A. (N.A)
Stock Futures Rise as Cyprus Deal Is Clinched

Stock Futures Rise as Cyprus Deal Is Clinched

Stock futures rise Monday with investors relieved that Cyprus is able to negotiate a last-minute bailout deal with international creditors.

Idenix Loses First Phase Of Patent Dispute With Gilead Sciences

Idenix Loses First Phase Of Patent Dispute With Gilead Sciences

Idenix alleges Gilead is violating a patent application for a hepatitis C treatment.

Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha

Fisking Ray Dirks on Medgenics and Shaming Seeking Alpha

A column promoting Medgenics and trashing other Hep C stocks is riddled with mistakes.

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

Biotech Stock Mailbag: Dynavax, ImmunoCellular, Celldex and Medgenics

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs

Idenix Pharmaceuticals Provides Update On IDX184 And IDX19368 Development Programs

Management to Host a Conference Call and Webcast Today at 4:30 pm ET

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

The Twitterverse's Biotech Stock Picks for 2013

The Twitterverse's Biotech Stock Picks for 2013

TheStreet's readers took to Twitter to offer their biotech stock predictions for 2013.

Nate Sadeghi's 2012 Biotech Stock Report Card

Nate Sadeghi's 2012 Biotech Stock Report Card

TheStreet columnist takes a look back at his best and worst biotech stock calls in 2012.

5 Breakout Stock Plays: Must-See Charts

5 Breakout Stock Plays: Must-See Charts

Focus on trend, price and volume, and the charts do all the talking.

Gilead, Abbott Unwrap Dueling Hep C Data (Updated)

Gilead, Abbott Unwrap Dueling Hep C Data (Updated)

The race is on to develop new, all-oral hepatitis C therapies to replace the need for injections.

Gilead, Abbott Unwrap Dueling Hep C Pill Data

Gilead, Abbott Unwrap Dueling Hep C Pill Data

The race is on to develop new, all-oral hepatitis C therapies to replace the need for injections.

Achillion Pharma Worthy of New Look

Achillion Pharma Worthy of New Look

The winnowing of competing hepatitis C drugs has made Achillion's pipeline more compelling.

Five Cystic Fibrosis Questions for Vertex Pharma

Five Cystic Fibrosis Questions for Vertex Pharma

Good answers to these questions Thursday will raise investor confidence in Vertex's cystic fibrosis program.

Vertex Advances One of Two Hep C Drugs

Vertex Advances One of Two Hep C Drugs

Vertex still trails Gilead Sciences and others in developing an an all-oral therapy for hepatitis C.

Idenix Pharma: Guilty By Association

Idenix Pharma: Guilty By Association

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks look ready to break out and trade higher from current levels.

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents At Morgan Stanley Global Healthcare Conference (Transcript)

Idenix Pharmaceuticals' CEO Presents at Morgan Stanley Global Healthcare Conference (Transcript)

The Essential 2012 Biotech Stock Fall Preview

The Essential 2012 Biotech Stock Fall Preview

If you're a biotech investor not following these stocks this fall, you're not paying attention.